Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Sells $16,117.92 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 546 shares of the business’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $29.52, for a total transaction of $16,117.92. Following the sale, the chief financial officer now owns 128,665 shares of the company’s stock, valued at approximately $3,798,190.80. The trade was a 0.42 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Wednesday, January 22nd, Timothy Eugene Sullivan sold 3,088 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $30.43, for a total transaction of $93,967.84.
• On Friday, January 17th, Timothy Eugene Sullivan sold 1,730 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $29.96, for a total transaction of $51,830.80.
• On Monday, January 13th, Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.70, for a total value of $62,279.00.

Apellis Pharmaceuticals Price Performance

NASDAQ:APLS opened at $29.01 on Friday. Apellis Pharmaceuticals, Inc. has a 52-week low of $24.34 and a 52-week high of $71.90. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The business’s 50-day moving average price is $32.21 and its 200 day moving average price is $32.81. The firm has a market cap of $3.61 billion, a P/E ratio of -14.29 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The business had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company’s quarterly revenue was up 78.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.17) earnings per share. As a group, sell-side analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Squarepoint Ops LLC purchased a new position in shares of Apellis Pharmaceuticals in the second quarter worth approximately $2,350,000. AQR Capital Management LLC grew its position in Apellis Pharmaceuticals by 337.3% during the 2nd quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock worth $9,177,000 after purchasing an additional 190,420 shares in the last quarter. Teachers Retirement System of The State of Kentucky acquired a new stake in Apellis Pharmaceuticals during the 2nd quarter valued at $725,000. Duncan Williams Asset Management LLC purchased a new stake in shares of Apellis Pharmaceuticals in the third quarter valued at $609,000. Finally, Handelsbanken Fonder AB boosted its position in shares of Apellis Pharmaceuticals by 15.5% in the third quarter. Handelsbanken Fonder AB now owns 27,600 shares of the company’s stock worth $796,000 after buying an additional 3,700 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Wall Street Analysts Forecast Growth

APLS has been the subject of a number of analyst reports. Mizuho reduced their price objective on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research report on Thursday, October 24th. Bank of America reduced their price target on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. The Goldman Sachs Group cut shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price objective on the stock. in a report on Tuesday, December 17th. Oppenheimer reduced their target price on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Finally, Piper Sandler dropped their price target on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $46.71.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).